Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 435
- Registration Number
- NCT06705504
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Conditions
- Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42494
- Registration Number
- NCT06671314
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1665
- Registration Number
- NCT06662812
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 376
- Registration Number
- NCT06662825
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3632
- Registration Number
- NCT06644638
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain
- Conditions
- Spinal Muscular Atrophy Type ISpinal Muscular Atrophy Type II
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 69
- Registration Number
- NCT06632730
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
- Conditions
- Essential Hypertension
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-09-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1405
- Registration Number
- NCT06604897
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 534
- Registration Number
- NCT06600009
- Locations
- 🇯🇵
Novartis Pharma K.K., Tokyo, Japan
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT06595069
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis
- Conditions
- Secondary Progressive Multiple Sclerosis
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 210
- Registration Number
- NCT06588387
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States